LexaGene Announces Webinar by UC Davis Professor on Use of MiQLab® System for Diagnosis of Urinary Tract Infections
05 July 2022 - 9:55PM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)
(“LexaGene” or the “Company”), a molecular diagnostics company that
has commercialized the MiQLab System for automated, multiplexing
PCR-based syndromic testing in veterinary clinics, is pleased to
announce that University of California-Davis (UC Davis) Professor
Dr. Jane Sykes BVSc (Hons), PhD, MBA, DACVIM (SAIM) will present a
webinar entitled, “The Wave of the Future: In-Clinic PCR
Diagnosis.” This will be a live event hosted by DVM360 and
moderated by Adam Christman, DVM, MBA. It is scheduled for Tuesday
July 26th at 7 PM EST. To register for the webinar, please click
HERE.
This webinar will provide background information
on the difficulties of accurately diagnosing urinary tract
infections with conventional technologies. Also, the course will
provide background information on the rising threat of
antimicrobial resistance. This will be followed by an overview of
PCR and how genomic testing can be used by veterinarians to make
rapid evidence-based decisions in the clinic by utilizing the
MiQLab System to rapidly screen samples for 10 common pathogens and
33 markers for antimicrobial resistance factors.
Dr. Sykes is a Professor of Small Animal
Internal Medicine (Infectious Diseases) and the Executive Director
of Innovation and Entrepreneurship in the School of Veterinary
Medicine (SVM) at UC Davis. Her research focus is infectious
diseases of dogs and cats, especially those of public health
significance.
Dr. Sykes hails from Melbourne, Australia. Dr.
Sykes received her veterinary degree and PhD at the University of
Melbourne and her MBA from the University of Georgia. She completed
her residency at the University of Minnesota. Dr. Sykes is a
Diplomate of the American College of Veterinary Internal Medicine
(SAIM) and has a California University Veterinarian Licensure. She
is the recipient of numerous awards and author of many
scientific publications.
To learn more about LexaGene and the MiQLab
System or subscribe to company updates, visit www.lexagene.com, or
follow us on Twitter or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
For inquiries: 800.215.1824 | ir@lexagene.com or
info@lexagene.com
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab® system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Apr 2023 to Apr 2024